Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Rating of “Hold” from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has earned an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $5.40.

GUTS has been the subject of a number of recent research reports. Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $8.00 to $2.00 in a research note on Thursday, January 29th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Tuesday, December 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th.

Institutional Investors Weigh In On Fractyl Health

Several large investors have recently modified their holdings of GUTS. Virtu Financial LLC acquired a new position in shares of Fractyl Health in the 4th quarter worth approximately $153,000. Susquehanna Portfolio Strategies LLC bought a new stake in Fractyl Health in the fourth quarter valued at $108,000. Quadrature Capital Ltd grew its position in Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after acquiring an additional 277,174 shares during the period. Millennium Management LLC raised its stake in Fractyl Health by 356.6% during the fourth quarter. Millennium Management LLC now owns 1,861,418 shares of the company’s stock worth $4,095,000 after acquiring an additional 1,453,751 shares in the last quarter. Finally, Catalio Capital Management LP raised its stake in Fractyl Health by 5.3% during the fourth quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock worth $12,082,000 after acquiring an additional 277,630 shares in the last quarter.

Fractyl Health Stock Down 3.7%

Fractyl Health stock opened at $0.48 on Monday. The business has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.34. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $3.03. The stock has a market cap of $65.78 million, a price-to-earnings ratio of -0.21 and a beta of 1.51.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.